Join us for a virtual CME on high risk thyroid cancer which remains a therapeutic challenge. This live, case-based panel discussion will cover the basics of high risk thyroid cancer from presentation and diagnosis to treatment. A comprehensive discussion on standard and advanced therapeutics will be included. The necessity of a multi-d advanced care team for the mgmt. of these patients will be emphasized.
Moderated by Susan Mandel, MD, the panel will include specialists from medical oncology, surgery, radiation oncology and nuclear medicine.
‣Understand the approaches for radioactive iodine therapy in aggressive thyroid cancer
‣Identify clinical scenarios where external beam radiation may be indicated
‣Gain familiarity with surveillance strategies for high-risk patients and indications for intervention
‣Recognize the role of systemic therapy in metastatic thyroid cancer
Marcia Brose, MD, PhD
Director of the Thyroid Cancer Therapeutics Program
Ara Chalian, MD
Director of Facial Plastic Surgery, Head and Neck Surgery
Samuel Swisher-McClure, MD, MSHP
Co-Director, Head & Neck Cancer Service Line
Daniel Pryma, MD
Chief, Division of Nuclear Medicine Imaging and Therapy
In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians: Penn Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits(TM). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance / Participation (1.00 hours)